Cart
sales@molnova.com
Eflucimibe
CAS No. 202340-45-2
Eflucimibe( —— )
Catalog No. M34231 CAS No. 202340-45-2
Eflucimibe (L0081) is an acyl coenzyme A: cholesterol acyltransferase inhibitor for the treatment of cardiovascular disease and endocrine and metabolic disorders, and can be used to study atherosclerosis and hyperlipidemia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 397 | In Stock |
|
| 5MG | 376 | In Stock |
|
| 10MG | 566 | In Stock |
|
| 25MG | 905 | In Stock |
|
| 50MG | 1200 | In Stock |
|
| 100MG | 1646 | In Stock |
|
| 200MG | 2223 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEflucimibe
-
NoteResearch use only, not for human use.
-
Brief DescriptionEflucimibe (L0081) is an acyl coenzyme A: cholesterol acyltransferase inhibitor for the treatment of cardiovascular disease and endocrine and metabolic disorders, and can be used to study atherosclerosis and hyperlipidemia.
-
DescriptionEflucimibe (F 12511) is a new acyl-coenzyme A cholesterol O-acyltransferase (ACAT) inhibitor. Eflucimibe can be used in the research of atherosclerosis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorAcyltransferase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number202340-45-2
-
Formula Weight469.72
-
Molecular FormulaC29H43NO2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[C@H](C(NC1=C(C)C(C)=C(O)C(C)=C1)=O)(SCCCCCCCCCCCC)C2=CC=CC=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Nathalie Mesplet, et al. Analysis of eflucimibe and related impurities by highly sensitive liquid chromatography-electrospray-tandem mass spectrometry. The Journal of Separation Science. 2003.
molnova catalog
related products
-
12-Didecanoyl-sn-gly...
12-Didecanoyl-sn-glycero-3-phosphocholi is a synthetic less hydrophobic phospholipid that has been found to be useful for enhancing the absorption of peptide drugs and hormones such as insulin.
-
pep2-EVKI
Inhibitor peptide that selectively disrupts binding of the AMPA receptor subunit GluA2 (at the C-terminal PDZ site) to protein interacting with C kinase (PICK1). Does not affect binding of GluA2 to GRIP or ABP and does not increase AMPA current amplitude or affect long term depression (LTD).
-
Ezutromid
The first orally bioavailable small molecule utrophin upregulator.
